Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYosr HicheriATAnne ThiebautFOFlorence Van Obbergh

Discussion

Loading...

Member takes

Overview

Analysis reveals blinatumomab consolidation improves relapse risk in high-risk Philadelphia chromosome-negative B-ALL patients, indicating a significant survival benefit.

Key Points

  • Blinatumomab consolidation significantly decreased relapse risk in high-risk B-ALL patients, enhancing treatment outcomes for durable remission.
  • Patients receiving blinatumomab showed a 3-year disease-free survival rate of 70%, compared to 48% in the control group, confirming effective consolidation.
  • This observational analysis across high-risk B-ALL cohorts highlights the improved rates of complete remission following blinatumomab treatment compared to historical controls.
  • The findings support blinatumomab's role in treating high-risk patients and call for further studies to explore its synergistic effects with transplant therapies.

Cite This Study

Hicheri et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d44ahttps://doi.org/10.1182/blood-2025-643
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis2025
  2. 2Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL17312025
  3. 3Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab2025 · 1 citations
  4. 4FDA Approval Summary: Blinatumomab for the Treatment of B-cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy2025 · 7 citations
  5. 5“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”2025